Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg QD for 5 Days Versus Placebo in the Treatment of Acute Bacterial Sinusitis

NCT00492024 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00492024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00492024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg QD for 5 Days Versus Placebo in the Treatment of Acute Bacterial Sinusitis
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
March 31, 2008
Enrollment
374 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

sinusitis